<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033951</url>
  </required_header>
  <id_info>
    <org_study_id>202000124</org_study_id>
    <nct_id>NCT05033951</nct_id>
  </id_info>
  <brief_title>Optimizing INITIation of Non-invasive Ventilation in ALS Patients</brief_title>
  <acronym>INITIALS</acronym>
  <official_title>Optimizing INITIation of Non-invasive Ventilation in ALS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The primary objective in this study is to identify which (pheno)type of ALS&#xD;
      patient has the most benefit from NIV in improving quality of life.&#xD;
&#xD;
      Study population: Adult patients with ALS, PLS (Primary Lateral Sclerosis) of PSMA&#xD;
      (Progressive Spinal Muscular Atrophy) in the Netherlands. Patients will be included during&#xD;
      their first visit to one of the HMV centres in the Netherlands.&#xD;
&#xD;
      Main study parameters/endpoints: The main study parameter is change in Quality of Life (QoL)&#xD;
      defined as change in ALS Assessment Questionnaire (ALSAQ-40) in patients with ALS after&#xD;
      initiation of NIV.&#xD;
&#xD;
      Design: Multi-centre prospective cohort study consisting of 2 non-randomized cohorts, i.e.&#xD;
      ALS patients who start NIV and ALS patients who do not start NIV at the time of inclusion in&#xD;
      the present study.&#xD;
&#xD;
      Duration: The total duration of the study: 3,5 years. Inclusion period: 30 months. Follow up&#xD;
      time after initiation of NIV: 9 months. Thereafter, 6 months will be used for data analysis.&#xD;
&#xD;
      Setting: Involvement of all (4) HMV centres in the Netherlands (Groningen, Maastricht,&#xD;
      Rotterdam, Utrecht).&#xD;
&#xD;
      Procedure: 250 ALS patients will be included. During the first regular visit to the HMV&#xD;
      centre patients will be asked to participate in the study. Data will be recorded during&#xD;
      regular visits to the HMV centre.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First visit:&#xD;
&#xD;
      After informed consent the following data which are gathered as parts of usual care will be&#xD;
      recorded in the case report form (CRF):&#xD;
&#xD;
        -  Pulmonary function:&#xD;
&#xD;
             -  FVC ( % predicted) upright and supine&#xD;
&#xD;
             -  capillary blood gas analysis, room air (pH, pCO2, HCO3-, pO2)&#xD;
&#xD;
             -  anamnestic questions (Borg scale 0-4)&#xD;
&#xD;
        -  Gender&#xD;
&#xD;
        -  Age&#xD;
&#xD;
        -  Percutaneous Endoscopic Gastrostomy (PEG)/ Percutaneous Radiological Gastrostomy (PRG)&#xD;
           tube: yes/no&#xD;
&#xD;
        -  Medication&#xD;
&#xD;
        -  Weight/ BMI&#xD;
&#xD;
        -  Living situation&#xD;
&#xD;
        -  Civil status&#xD;
&#xD;
        -  The following clinical characteristics from their medical record (from neurologist or&#xD;
           rehabilitation specialist):&#xD;
&#xD;
             -  Date of diagnosis&#xD;
&#xD;
             -  Type of ALS at onset&#xD;
&#xD;
             -  ALSFRS-R at the time of diagnosis&#xD;
&#xD;
             -  Pulmonary function at the time of diagnosis&#xD;
&#xD;
             -  Cognitive status (ECAS, ALS-FTD-Q)&#xD;
&#xD;
             -  Medical history&#xD;
&#xD;
        -  Validated questionnaires (online):&#xD;
&#xD;
             -  Quality of life questionnaires (SF 36, ALSAQ-40)&#xD;
&#xD;
             -  Respiratory insufficiency questionnaire (SRI)&#xD;
&#xD;
             -  ALS FRS R (patient version)&#xD;
&#xD;
             -  Bulbar symptoms questionnaire (CNS BFS)&#xD;
&#xD;
      After the first visit patients will participate in one of the two cohorts (non-randomized):&#xD;
&#xD;
        -  Cohort 1: patients who start NIV in the first two months after the first visit to the&#xD;
           HMV&#xD;
&#xD;
        -  Cohort 2: patients who do not start NIV in the first two months after the first visit to&#xD;
           the HMV.&#xD;
&#xD;
      Cohort 1:&#xD;
&#xD;
      Data will be recorded at the moment of initiation of NIV and 3, 6 and 9 months after&#xD;
      initiation. Data will be recorded during regular visits (to the HMV centre or at the patients&#xD;
      home).&#xD;
&#xD;
        -  Pulmonary function:&#xD;
&#xD;
             -  capillary blood gas, room air (pH, pCO2 (kPa/ mmHg), HCO3- (mmol/l), SaO2 (%))&#xD;
&#xD;
             -  anamnestic questions (Borg scale 0-4)&#xD;
&#xD;
             -  Nocturnal gas exchange by transcutaneous measurement, at the patients home - Mean&#xD;
                tcpCO2 (kPa), Maximal tcpCO2 (kPa), mean oxygen saturation (%), lowest oxygen&#xD;
                saturation (%)&#xD;
&#xD;
        -  Data from NIV equipment (compliance, modus, IPPA, EPAP, freq, mask type)&#xD;
&#xD;
        -  Use of NIV&#xD;
&#xD;
             -  hours a day/night&#xD;
&#xD;
             -  In case of no use: why not?&#xD;
&#xD;
        -  PEG/ PRG tube: yes/no&#xD;
&#xD;
        -  Survival&#xD;
&#xD;
        -  Tracheostomy or not&#xD;
&#xD;
        -  Weight&#xD;
&#xD;
        -  Validated online questionnaires:&#xD;
&#xD;
             -  Quality of life questionnaires (SF 36, ALSAQ-40)&#xD;
&#xD;
             -  Respiratory insufficiency questionnaire (SRI)&#xD;
&#xD;
             -  ALS FRS R (patient version)&#xD;
&#xD;
             -  Bulbar symptoms questionnaire (CNS BFS)&#xD;
&#xD;
        -  Nocturnal gas exchange, transcutaneous, at the patients home&#xD;
&#xD;
      Cohort 2:&#xD;
&#xD;
      Data will be recorded every 3 months until initiation of NIV or death or max 1,5 years after&#xD;
      the first visit to the HMV.&#xD;
&#xD;
      Data will be recorded during regular visits (to the HMV centre or at the patients home).&#xD;
&#xD;
        -  Pulmonary function:&#xD;
&#xD;
             -  Capillary blood gas (pH, pCO2 (kPa/ mmHg), HCO3- (mmol/l), SaO2 (%))&#xD;
&#xD;
             -  anamnestic questions (Borg scale 0-4)&#xD;
&#xD;
             -  Nocturnal gas exchange by transcutaneous measurement, at the patients home - tcpCO2&#xD;
                (kPa), Maximal tcpCO2 (kPa), oxygen saturation (%), lowest oxygen saturation (%)&#xD;
&#xD;
        -  PEG/ PRG tube: yes/no&#xD;
&#xD;
        -  Survival&#xD;
&#xD;
        -  Tracheostomy or not&#xD;
&#xD;
        -  Weight&#xD;
&#xD;
        -  Cognitive status (from medical record)&#xD;
&#xD;
        -  Reason for not starting NIV&#xD;
&#xD;
        -  Validated online questionnaires:&#xD;
&#xD;
             -  Quality of life questionnaires (SF 36, ALSAQ-40)&#xD;
&#xD;
             -  Respiratory insufficiency questionnaire (SRI)&#xD;
&#xD;
             -  ALS FRS R (patient version)&#xD;
&#xD;
             -  Bulbar symptoms questionnaire (CNS BFS)&#xD;
&#xD;
        -  Nocturnal gas exchange, transcutaneous, at the patients home&#xD;
&#xD;
      If a patient in cohort 2 will start with NIV, the patient will be transferred to cohort 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>42 Months</target_duration>
  <primary_outcome>
    <measure>Health related Quality of Life in patients with ALS</measure>
    <time_frame>15 months</time_frame>
    <description>Assessed by Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) Min score: 0 Max score: 160 Higher scores mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>15 months</time_frame>
    <description>Determine the effect of NIV on survival in patients with different ALS phenotypes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall function</measure>
    <time_frame>15 months</time_frame>
    <description>Overall function decline based on the ALS Functional Rating Scale Revised (ALS-FRS-R).&#xD;
Min score: 0 Max score: 48 Higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>15 months</time_frame>
    <description>Pulmonary function based on FVC Min score: 0% Max score: 100% Lower scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbondioxide</measure>
    <time_frame>15 months</time_frame>
    <description>Pulmonary function based on carbondioxide pCO2 in capillary bloodgas Min score: 4 kPa Max score: 9 kPa Higher score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anamnestic questions</measure>
    <time_frame>15 months</time_frame>
    <description>Pulmonary function based on anamnestic questions, Borg scale Min score: 0 Max score: 40 Higher score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bulbar function</measure>
    <time_frame>15 months</time_frame>
    <description>Bulbar function based on questionnaire Center for Neurological Study Bulbar Functional Scale (CNS BFS).&#xD;
Min score: 21 Max score: 105 Higher scores means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>15 months</time_frame>
    <description>Weight in kg Min score: 40 Max score 130 Lower scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health Quality of Life in patients with severe respiratory insufficiency</measure>
    <time_frame>15 months</time_frame>
    <description>Assessed by severe respiratory insufficiency questionnaire (SRI) Min score: 49 Max score: 245 Higher scores mean worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health Quality of Life</measure>
    <time_frame>15 months</time_frame>
    <description>Assessed by in Short Form Health Survey (SF-36) Min score: 45 Max score: 198 Higher score means a worse outcome</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Patients who start NIV in the first two months after the first visit to the HMV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Patients who do not start NIV in the first two months after the first visit to the HMV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Both groups: standard care+ questionnaires</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must be diagnosed with Amyotrophic Lateral Sclerosis (ALS), Progressive Spinal&#xD;
        Muscular Atrophy (PSMA) or Primary Lateral Sclerosis (PLS) by a neurologist.&#xD;
&#xD;
        The patients will be included (after signing informed consent) during the first visit to&#xD;
        one of the HMV centres in the Netherlands. Patients must to be able to participate and at&#xD;
        least 18 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Diagnosis of ALS, PLS or PSMA&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
          -  Ability to fill in the questionnaires independently or with assistance of a caregiver.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of NIV or invasive ventilation (tracheostomy) at time of first visit to a HMV&#xD;
             centre.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rineke Jaspers Focks, MD</last_name>
    <phone>+31534875424</phone>
    <email>r.jaspersfocks@roessingh.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Wijkstra, MD, PhD</last_name>
    <phone>+31503613200</phone>
    <email>p.j.wijkstra@umcg.nl</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Peter Wijkstra</investigator_full_name>
    <investigator_title>Prof. Dr. P.J. Wijkstra</investigator_title>
  </responsible_party>
  <keyword>Noninvasive ventilation</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

